Stock Market Stories and Insights

<div class='circular--portrait-small' style='font-weight: 700;background:#169D0B;color: #E6E6FA;font-size:1.1em;padding-top: 10px;;'>AC</div>
  few days ago at Macroaxis 
By Gabriel Shpitalnik
AeroCentury Corp is scheduled to announce its earnings today. Because some of us are getting excited about industrials space, it makes sense to break down AeroCentury Corp in greater detail. We will analyze why AeroCentury Corp investors may still consider a stake in the business given the current current
<div class='circular--portrait-small' style='font-weight: 700;background:#800000;color: #F8F8FF;font-size:1.1em;padding-top: 10px;;'>AT</div>
  few days ago at Macroaxis 
By Ellen Johnson
It seems Abeona Therapeutics may not have a good chance to recover from the latest slide as its shares fell again. The company's current daily volatility is 4.6 percent, with a beta of 0.51 and an alpha of 0.28 over DOW. As many millenniums are excited about the latest volatility, it is fair to outline Abeona Therapeutics based on its historical price patterns. We will cover the possibilities of making Abeona Therapeutics into a steady grower in September.
<div class='circular--portrait-small' style='font-weight: 700;background:#800000;color: #F8F8FF;font-size:1.1em;padding-top: 10px;;'>AT</div>
  few days ago at Macroaxis 
By Achuva Shats
Abeona Therapeutics PPandE Turnover is quite stable at the moment as compared to the past year. The company's current value of PPandE Turnover is estimated at 0.66. Receivables Turnover is expected to rise to 30.97 this year, although the value of Net Income Per Employee will most likely fall to (935.3 K). In this article, we will outline Abeona Therapeutics. We will evaluate why we are still optimistic in anticipation of a recovery. In this post, I will also go over some essential variables affecting Abeona Therapeutics' products, and show how it may impact Abeona Therapeutics outlook for active traders this year.
<div class='circular--portrait-small' style='font-weight: 700;background:#FF6600;color: #f7f7f7;font-size:1.1em;padding-top: 10px;;'>NB</div>
  3 days ago at Macroaxis 
By Achuva Shats
NORTHWEST BIOTHERAPEUTICS PPandE Turnover is quite stable at the moment as compared to the past year. The company's current value of PPandE Turnover is estimated at 0.0161. Accounts Payable Turnover is expected to rise to 0.0217 this year, although the value of Net Income Per Employee will most likely fall to (6.2 M). The goal of this thesis is to forecast a future value of NORTHWEST BIOTHERAPEUTICS using technical analysis. What exactly are NORTHWEST BIOTHERAPEUTICS institutional investors should expect in September?
<div class='circular--portrait-small' style='font-weight: 700;background:#347AFC;color: #ffffff;font-size:1.1em;padding-top: 10px;;'>SP</div>
  3 days ago at Macroaxis 
By Gabriel Shpitalnik
As many millenniums are trying to avoid healthcare space, it makes sense to outline Supernus Pharmaceuticals a little further and try to understand its current market patterns. We will analyze why it could be a much better year for Supernus Pharmaceuticals shareholders. Is the entity valuation sustainable? Here I will cover a perspective on valuation of Supernus to give you a better outlook on taking a position in this stock.
<div class='circular--portrait-small' style='font-weight: 700;background:#754DEB;color: #F0FFF0;font-size:1.1em;padding-top: 10px;;'>CW</div>
  few days ago at Macroaxis 
By Achuva Shats
Why analysts lower the firm buy or sell consensus to Buy? Consolidated Water is scheduled to announce its earnings today. The upcoming quarterly report is expected on the 10th of August 2020. Because some of us are getting excited about utilities space, it makes sense to outline Consolidated Water Co in greater detail. We will evaluate why we are still optimistic in anticipation of a recovery. Analysts now have less confidence in Consolidated Water as compared to a month ago. The current buy or sell recommendation of 2 analysts is Buy.
<div class='circular--portrait-small' style='font-weight: 700;background:#169D0B;color: #E6E6FA;font-size:1.1em;padding-top: 10px;;'>AC</div>
  3 days ago at Macroaxis 
By Vlad Skutelnik
While some planning is required to successfully invest in stocks, sometimes taking bold action is just as important. Let's try to break down why this may be the case with AeroCentury Corp. We will evaluate why recent AeroCentury Corp price moves suggest a bounce in September. On the 9th of August the company is traded for 3.16. AeroCentury Corp has historical hype elasticity of -0.41. The average price elasticity to hype of competition is about 0.15. The entity is forecasted to increase in value after the next press release, with the price going to jump to 4.5274. The current volatility of headline impact on AeroCentury Corp stock price is is way over 100 percent making price predictions on social media along less reliable. The price jump on the next news is expected to be 43.27%, whereas the daily expected return is presently at 2.06%. Considering the 30-days investment horizon, the next forecasted announcement will be in about 3 days.
<div class='circular--portrait-small' style='font-weight: 700;background:#FF6600;color: #FFFAFA;font-size:0.9em;padding-top: 12px;;'>TGN</div>
  3 days ago at Macroaxis 
By Raphi Shpitalnik
As many baby boomers are indifferent towards communication services space, it makes sense to go over TEGNA Inc against current market trends. As expected, TEGNA is starting to reaffirm its true potential as investors are becoming more and more confident in the future outlook. The returns on investing in TEGNA and the market returns of the last few months appear uncorrelated. Weak basic indicators of the company may also suggest signs of long term losses for TEGNA investors. TEGNA Inc is scheduled to announce its earnings tomorrow. The upcoming quarterly report is expected on the 10th of August 2020.
<div class='circular--portrait-small' style='font-weight: 700;background:#FF0F00;color: #FFFFF0;font-size:1.1em;padding-top: 10px;;'>IS</div>
  few days ago at Macroaxis 
By Ellen Johnson
A current spike in volatility has left many investors looking confused. In this story, we will break down IMAGEWARE SYSTEMS INC. We will evaluate why we are still confident in anticipation of a recovery. IMAGEWARE SYSTEMS INC is currently traded for 0.11. The entity stock is not elastic to its hype. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is currently at -0.01%. The volatility of relative hype elasticity to IMAGEWARE SYSTEMS is about 14250.0%. Given the investment horizon of 30 days, the next forecasted announcement will be in about 4 days.
<div class='circular--portrait-small' style='font-weight: 700;background:#3b5998;color: #F0F8FF;font-size:1.1em;padding-top: 10px;;'>BT</div>
  few days ago at Macroaxis 
By Raphi Shpitalnik
25% of stocks are less volatile than BioSpecifics, and 97% of all traded equity instruments are projected to make higher returns than the company over the 60 days investment horizon. While many risk-averse investors are getting carried away by overanalyzing healthcare space, it is reasonable to go over BioSpecifics Technologies Corp. We will analyze how risky is to take a position in BioSpecifics Technologies at this time. BioSpecifics Technologies' low volatility may still impact the value of the stock as we estimate it as currently undervalued. The real value, based on our analysis, is getting close to 77.25 per share.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page